Seagen

Seagen vs. Daiichi Sankyo marks a major setback for broad biologics genus claims as the Federal Circuit overturned Seagen’s $41.8M jury verdict, invalidating US10808039B2 for lack of written description and enablement under the post Amgen v. Sanofi standard.